300 related articles for article (PubMed ID: 36661704)
1. Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.
Doumat G; Daher D; Zerdan MB; Nasra N; Bahmad HF; Recine M; Poppiti R
Curr Oncol; 2023 Jan; 30(1):704-719. PubMed ID: 36661704
[TBL] [Abstract][Full Text] [Related]
2. Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.
Karuppasamy R; Veerappapillai S; Maiti S; Shin WH; Kihara D
Semin Cancer Biol; 2021 Jan; 68():84-91. PubMed ID: 31698087
[TBL] [Abstract][Full Text] [Related]
3. Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks.
Qin S; Li W; Yu H; Xu M; Li C; Fu L; Sun S; He Y; Lv J; He W; Chen L
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768566
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.
Bahmad HF; Daher D; Aljamal AA; Elajami MK; Oh KS; Alvarez Moreno JC; Delgado R; Suarez R; Zaldivar A; Azimi R; Castellano A; Sackstein R; Poppiti RJ
J Histochem Cytochem; 2021 Dec; 69(12):749-773. PubMed ID: 34165342
[TBL] [Abstract][Full Text] [Related]
5. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory.
Huang CH; Chang PM; Hsu CW; Huang CY; Ng KL
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):2. PubMed ID: 26817825
[TBL] [Abstract][Full Text] [Related]
6. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
Yang XG; Li YY; Zhao DX; Cui W; Li H; Li XY; Li YX; Wang D
Oncol Rep; 2021 Mar; 45(3):1306-1314. PubMed ID: 33650669
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing towards targeting cancer stem cells in pediatric brain tumors.
Bahmad HF; Elajami MK; El Zarif T; Bou-Gharios J; Abou-Antoun T; Abou-Kheir W
Cancer Metastasis Rev; 2020 Mar; 39(1):127-148. PubMed ID: 31919619
[TBL] [Abstract][Full Text] [Related]
11. Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.
Rajasegaran T; How CW; Saud A; Ali A; Lim JCW
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986550
[TBL] [Abstract][Full Text] [Related]
12. Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast.
Ochi K; Suzawa K; Thu YM; Takatsu F; Tsudaka S; Zhu Y; Nakata K; Takeda T; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Shien T; Okamoto Y; Tomida S; Toyooka S
Cancer Sci; 2022 Oct; 113(10):3428-3436. PubMed ID: 35871750
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
16. Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes.
Parvathaneni V; Elbatanony RS; Goyal M; Chavan T; Vega N; Kolluru S; Muth A; Gupta V; Kunda NK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946414
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing-an emerging strategy in cancer therapeutics.
Turabi KS; Deshmukh A; Paul S; Swami D; Siddiqui S; Kumar U; Naikar S; Devarajan S; Basu S; Paul MK; Aich J
Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1139-1158. PubMed ID: 35695911
[TBL] [Abstract][Full Text] [Related]
18. A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.
Jayan AP; Anandu KR; Madhu K; Saiprabha VN
Med Oncol; 2022 Jul; 39(10):147. PubMed ID: 35834033
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art.
Paliogiannis P; Fois SS; Fois AG; Cossu A; Palmieri G; Pintus G
Curr Med Chem; 2021; 28(11):2234-2247. PubMed ID: 32748739
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer stem cells as a target for therapy.
Gorelik E; Lokshin A; Levina V
Anticancer Agents Med Chem; 2010 Feb; 10(2):164-71. PubMed ID: 20184538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
